Adeno-associated virus vectors for gene therapy

Area of Science:

• Molecular Biology
• Virology
• Biotechnology

Background:

• Adeno-associated virus type 2 (AAV) is a non-pathogenic DNA virus.
• AAV serves as a eukaryotic gene transfer vector for in vitro and in vivo applications.
• Its unique characteristics suggest potential for human gene therapy.

Purpose of the Study:

• To evaluate the potential of AAV as a gene therapy vector.
• To investigate AAV transduction and expression in the lungs for cystic fibrosis (CF) gene therapy.
• To assess the safety and efficacy of AAV vectors in preclinical models.

Main Methods:

• AAV vectors were used to transduce various cell types in vitro.
• In vivo studies involved direct delivery of AAV vectors to the airway surface of rodents and non-human primates.
• Integration and persistence of AAV vectors in host cells were analyzed.

Main Results:

• AAV vectors demonstrated successful transduction and expression in a wide range of cell types.
• In vivo studies showed AAV transduction and expression in the lungs of preclinical models without detectable toxicity.
• AAV vectors persist in infected cells long-term with no significant adverse effects.

Conclusions:

• AAV vectors are effective for gene transfer in various cell types and preclinical lung models.
• AAV-based gene therapy holds significant potential for treating genetic disorders like cystic fibrosis.
• The safety profile and efficacy of AAV vectors support their advancement into human clinical trials, with a phase I trial for CF approved.